A cohort study involving 8207 patients with various tumor types, including bladder cancer, non‐small cell lung cancer, melanoma, etc., showed that high TMB was associated with prolonged OS after anti‐PD‐1/PD‐L1 and/or anti‐CTLA4 treatment, and the treatment benefits increased with the increase in TMB value.45 Here, PDCD1 is linked to urinary bladder carcinoma.